Sign In
Buy ENDO
$0.0001
+0 (+0%)
At Close: Jun 03, 2026
Analyses span adult and pediatric populations with classic congenital adrenal hyperplasia (CAH) and reflect longer-term clinical outcomes relevant to disease management across lifespan and care contin
Crinetics' Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations
04:55am, Tuesday, 02'nd Jun 2026
Oral presentation features open label extension PALSONIFY™ (paltusotine) data, reinforcing its best-in-class potential in acromegaly following recent U.S. and E.U. approvals
Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026
08:00am, Friday, 29'th May 2026
BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare
Approximately 95% of adult and pediatric patients were exposed to supraphysiologic doses of glucocorticoids and/or experienced elevated androstenedione levels at least once during their treatment jour
Aspect Biosystems Presents New Preclinical Data on Adrenal Bioprinted Tissue Therapeutics at ENDO 2025
04:45pm, Monday, 14'th Jul 2025
VANCOUVER, British Columbia--(BUSINESS WIRE)-- #biotech--Aspect Biosystems presents preclinical data showing potential of its adrenal BTTs to restore adrenal function and treat primary adrenal insuffi
One-year data from CAHtalyst™ Adult study demonstrated lasting reductions in glucocorticoid dose and improvement in clinical outcomes in adults with classic congenital adrenal hyperplasia Results b
SAN JOSE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the ora
OMass Therapeutics Presents Positive Preclinical Data For its Best-in-class MC2 Program at ENDO 2025
03:00am, Monday, 14'th Jul 2025
PRESS RELEASE OMass Therapeutics Presents Positive Preclinical Data For its Best-in-class MC2 Program at ENDO 2025 OMS1620 is advancing through IND-enabling studies for diseases associated with ACTH e
Data show that PALSONIFY was well tolerated and IGF-1 levels remained stably controlled during long-term open label extensions of PATHFNDR-1 and PATHFNDR-2 studies
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the presentation of new exploratory analyses from the Phase 2 PREVENT
Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025
06:00pm, Saturday, 12'th Jul 2025
- Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity – - Full data from Phase 3 TRANSCEND study underscore potential efficacy of setmelano
Amylyx Pharmaceuticals to Host Event to Discuss Post-bariatric Hypoglycemia and Avexitide at ENDO 2025
07:00am, Tuesday, 08'th Jul 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Host Event to Discuss Post-bariatric Hypoglycemia and Avexitide at ENDO 2025.
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ENDO 2025
04:01pm, Monday, 07'th Jul 2025
COPENHAGEN, Denmark, July 07, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced two oral presentations at ENDO 2025, the annual meeting of the Endocrine Society being held Ju
Long-term efficacy and safety data on PALSONIFY TM (paltusotine) in acromegaly to be presented, including evidence of both biochemical and symptom control with a well-tolerated safety profile in patie
Rhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025
08:00am, Wednesday, 25'th Jun 2025
BOSTON, June 25, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with ra
